Repurposing Seleno-L-Methionine as a Pleiotropic Immunomodulatory Agent to Overcome TGF-β1/HIF-Driven Immune Evasion in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Translational Therapeutic Opportunities

Youcef M. Rustum · 2026

Read Repurposing Seleno-L-Methionine as a Pleiotropic Immunomodulatory Agent to Overcome TGF-β1/HIF-Driven Immune Evasion in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Translational Therapeutic Opportunities by Youcef M. Rustum (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13565954.txt.

Description

Youcef Rustum argues, in twenty twenty-six, for repurposing a selenium compound to fight immune evasion in clear cell kidney cancer. This cancer often shrugs off immune checkpoint drugs, and cell therapies struggle too. A gene loss common in it keeps two pathways, TGF-beta and HIF, switched on. Together they drive blood vessel growth, metabolic rewiring, and immune escape. They raise suppressive signals that keep T cells out and exhaust them. The compound, seleno-L-methionine, at drug-level doses, suppressed both pathways in preclinical studies.

Its active metabolite also lowered the downstream suppressive signals, at safe, reachable doses. Prior evidence shows it boosts chemotherapy and vessel-targeted drugs. The review gathers signs that it may also restore immune attack, opening a translational path for this hard-to-treat cancer.

Catalog record

CREATORYoucef M. Rustum
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE53 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13565954

Browse the full library · About the Tower of Babel